Pain and inflammatory conditions are very often the main direct or underlying reasons why people seek medical care, and such conditions become even more common with ageing. medicine might offer such alternatives, but the evidence must be based on pharmacologic properties and on clinical trial data. This review summarizes the evidence for one of these: the analgesic properties of turmeric and other curcumins.
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| ME THODS
A MEDLINE/PubMed search was conducted for the period 1946-2018 using specific search terms such as turmeric (~3000 hits), curcumin (~9400 hits), and analgesia or antinociception (~66 500 hits). The Boolean search of turmeric OR curcumin AND analgesia OR antinociception yielded 16 hits. Additional searches sought general information from reviews on pain (eg pathways and types), analgesics [opioids, NSAIDs, acetaminophen (paracetamol), etc.], and turmeric and curcumin (eg composition, pharmacokinetics, formulations, mechanism of action (pharmacodynamics) and toxicologysafety-adverse effects. The searches included articles written on basic science, preclinical in vitro and in vivo testing, and clinical trials.
References within identified articles led to further sources (in print or available on the Internet). Each English-language article (~100) was assessed and included if applicable to the topic.
| RE SULTS
Turmeric is obtained from the herbaceous perennial plant Curcuma longa, which is a member of the ginger family. It is native to southwest India and has many applications-medicinal, religious and culinary (eg in curry powder). 5 Turmeric is often referred to as the "golden spice" and is used for a wide range of ailments. Importantly, it has reportedly minimal adverse effects. 5 Its use is now widespread in the world, 6 where it is also used as a dye (yellow-orange) and to create temporary designs on the skin, in the perfume industry for its mild aroma, and as a skin softener in soaps and lotions.
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| Composition of turmeric
Turmeric contains several classes of biologically active substances, for example curcuminoids (linear diarylheptanoids such as curcumin or derivatives of curcumin) including curcumin (diferuloyl methane, demethoxycurcumin and bisdemothoxy curcumin), plus other phytochemicals, volatile oils (eg, turmerone, atlantone, zingiberene), sugars, proteins and resins. 7 Curcumin (diferuloylmethane) (Figure 1) comprises approximately 2%-5% of the total composition of turmeric, is the component that imbues it with its vibrant deep yellow colour and is believed to be the major active therapeutic agent. 
| Pharmacokinetics: ADME (absorption, distribution, metabolism and elimination)
In animal studies, curcumin shows only limited systemic bioavailability following oral administration. This is due to poor absorption and rapid metabolism and excretion. 8 For example, a peak plasma concentration of only 1.8 mg/mL of curcumin was measured in rats when a 500 mg/kg oral dose was administered, and there was al- There are only a few studies that have evaluated the pharmacokinetic properties of curcumin comprehensively in humans. A study that compared the metabolism of curcumin in humans and rats reported that curcumin is extensively metabolized to its sulphate and glucuronide conjugates and reduced to hexahyrocurcumin and tetraydrocurcumin in the intestinal lumen in both species, but the gastrointestinal metabolism of curcumin conjugates is more extensive in humans than in rats. 9 Some human studies, like the rodent studies, suggest poor gastrointestinal absorption and a consequently poor systemic bioavailability which is more evident at lower doses. In one such study, subjects were given an initial 500 mg daily dose of curcumin which over time was increased to a maximum dose of 8000 mg daily. The lowest serum levels of curcumin, almost undetectable in some cases, were observed in subjects receiving 500-2000 mg daily. A mean serum curcumin level of 1.77 ± 1.87 μm was observed in subjects who received the maximum dose. For subjects receiving daily doses of 4000 mg and 6000 mg, serum concentrations of curcumin were 0.51 ± 0.11 μm and 0.63 ± 0.06 μm, respectively. 10 A study of 12 subjects given either 10 g (n = 6) or 12 g (n = 6) curcumin orally suggests that curcumin has better oral absorption at higher doses than at lower doses and that the levels in plasma are detected as curcumin sulphate and curcumin glucuronide, with curcumin glucuronide being predominant.
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It has been suggested that the bioavailability of curcumin can be improved by addition of adjuvants that block its degradative metabolic pathways. For example, when curcumin was combined with hydrophilic carriers, cellulosic derivatives and natural antioxidants, serum concentration of curcumin was significantly increased in 12 healthy volunteers, 12 but when the curcumin was administered alone, serum concentration of curcumin was barely detectable in humans. 13 When piperine (which is an inhibitor of glucuronidation in the liver and the intestine) was co-administered with curcumin to humans, there was a statistically significant increase in the serum concentration of curcumin at 0.75 hour post-administration (P < .01). curcuminoids. 15 In another study, theracurcumin (a novel nanoparticle with high water solubility) showed increased plasma concentration and improved bioavailability relative to free curcumin at doses up to 210 mg in humans. 16 A recent study suggested that there is a significant increase in the solubility of both the simple mixture and nanosuspension of curcumin in Tween ® 80 compared to pure curcumin. The water solubility of a mixture and nanosuspension of 22.2% curcumin in Tween ® 80 was 216-fold and 1936-fold higher than that of the pure curcumin. 17 Unfortunately, there were no data 
| Preclinical studies
In a study by Neha et al 21 the antinociceptive and antipyretic activities of rhizome extracts of C. longa were determined. Thirty-six rats of both sexes (150-200 g) were divided into six groups, and either saline (as the control) or aqueous or alcoholic extracts of turmeric were administered to each of the groups for 7 days. Analgin (metamizole sodium) was used to test for analgesic activity in the tail-immersion method as described by Gosh, 22 and paracetamol was used to screen for antipyretic activity using the method of Bhalla et al 23 The analgesic efficacy of the aqueous and alcoholic turmeric extracts at 100 and 200 mg/kg single oral dose was comparable to that of analgin. However, no antipyretic effect was observed at the same dose. hot-plate test, 25 and the anticonception induced by the synthetic curcumin analogue 2,6-bis-(4-hydroxy-3-methoxy-benzylidene)-cy clohexanone in the mouse acetic acid-induced abdominal constriction, formalin, and hot-plate tests. 33 The curcumin-induced antinociception in the rat formalin test is attenuated by glibenclamide, but not by L-NAME or ODQ, implicating ATP-sensitive K + channels, but not nitric oxide or soluble cGMP in the antinociception.
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PLGA-curcumin inhibited morphine tolerance and dependence in a 
| Clinical studies
A clinical observational study of patients (N = 820) with osteoarthritis monitored the analgesic effect of Flexofytol ® for more than 6 months (Flexofytol ® is a novel licensed formulation of a galenic form of curcumin which uses a thin dispersion of curcumin in specific excipient and emulsifiers that enhance intestinal absorption).
The study reported that Flexofytol ® is effective for joint pain and oedema associated with osteoarthritis. It was also reported that there was an improvement in patients' pain level, articular mobility and the quality of life in patients on Flexofytol ® within the first 6 weeks leading to a high degree of patient satisfaction. The dosage of Flexofytol ® used in this study (4-6 capsules per day) was tolerated by all patients, and more than half of them were able to discontinue concomitant use of analgesic, anti-inflammatory and chondroprotective drugs. The results also suggested a potential positive effect on cartilage regeneration, with clinical improvement maintained for up to 6 months, despite the reduction in concomitant use of analgesics and anti-inflammatory drugs. A limitation of the study is that it was observational and not randomized, placebo-controlled, double-blind study; however, the data collection was from a large number of physicians and patients over a relatively long period of observation.
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A double-blind randomized placebo-control study of 50 subjects that were post-laparoscopic cholecystectomy surgery was conducted to evaluate the efficacy of turmeric in pain and postoperative fatigue after surgery. A standard general anaesthesia and perioperative analgesia protocol was used. The label-blind curcumin or placebo was administered orally at a dose of one 500 mg capsule once every 6 hours for 3 weeks. The patients were asked to maintain diaries to record pain, fatigue or any adverse event. An event was recorded on a scale of 100-point visual analogue scale (VAS) for pain and 10-point interval rating scale (IRS) for fatigue. At 3 weeks, all of the patients on curcumin were pain free, and the analgesic use by patients taking curcumin was significantly lower than those on the control.
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At least two trials have been reported that demonstrate the antiinflammatory effects of turmeric. One evaluated the effect of curcumin on spermatic cord oedema. In this trial, the subjects (N = 46 men), 15-68 years old, were post-surgical inguinal hernia repair.
They were randomly assigned to three groups and received either 400 mg of curcumin, 100 mg phenylbutazone or 250 mg of lactose (placebo), three times daily for 5 days. The men were assessed for spermatic cord oedema, spermatic cord tenderness, operative site pain and operative site tenderness as reflected by intensity scores (TIS) 0-12. Curcumin proved to be superior in reducing inflammation according to the four parameters assessed. Overall, curcumin was found to be a safer and better anti-inflammatory agent compared to phenylbutazone. 36 A second trial examined eight subjects with idiopathic inflammatory orbital tumours who were given 375 mg of curcumin orally three times daily for 6-22 months. Three subjects dropped out of the trial, and the remaining five subjects were regularly assessed at 3-month intervals for up to 2 years until there was a complete regression of symptoms. One subject was asymptomatic with some limitation in ocular movement persisting; the remaining subjects experienced full recovery without any limitations or recurrences. 
| Safety
Turmeric is currently listed by the United States Food and Drug Administration (FDA) as "generally recognized as safe" (GRAS) for use as a colouring and flavouring agent in food. Curcumin itself is not listed. 38 However, its widespread use in food even in high doses without known adverse effects suggests its safety. 39 The use of turmeric, or its extracts or supplements has not been studied in children, so there are no recommended paediatric doses. 40 Human clinical trials have indicated no dose-limiting toxicity when doses up to 12 g/d were administered. In one of these studies, there was an increase in absorption and no recorded toxicity at 10 mg and 12 mg oral doses; another study reported that doses of up to 8000 mg/d
were well-tolerated, although higher doses were difficult to tolerate because of their bulky volume. 10, 11 In a short-term study of 24 subjects receiving curcumin in 1-12 g doses, 7 subjects developed minor adverse effects, including diarrhoea (n = 2), headache (n = 2), rash (n = 1) or yellow stool (n = 2), 41 and 2 of 15 patients in another study developed mild gastrointestinal adverse effects of diarrhoea (n = 1) and nausea (n = 1). 42 Turmeric may cause skin reactions, such as allergic contact dermatitis, a finding reported in a case study involving the use of turmeric powder mixed with a small amount of lime. 43 There are no studies to our knowledge that report the long-term adverse effect profile of curcumin. It is thus prudent to be cautious of any potential interactions associated with taking turmeric or its extracts as a supplement. 
| Potential adverse effects or drug interactions
The following are some potential adverse effects that should be further studied to assess the degree or extent (eg identify possible susceptible individuals) of clinical relevance:
• an allergic dermatitis, 44 • a possible developmental neurotoxic potential of curcumol,
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• inhibition of sperm motility and function, potentially resulting in reduction in fertility, 46 • iron chelation and stimulation of iron metabolism, resulting in reduced systemic iron, further exacerbating an existing iron deficiency leading to iron deficiency anaemia (since iron has a major role in the transport of oxygen in the blood)-this is not currently a contraindication, but further human studies are necessary to adequately assess the effects of curcumin on iron stores, 47, 48 • hypoglycaemic potential.
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• anticoagulant effects that reduce blood clotting in vitro; though such effects have not been demonstrated in vivo.
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| Dosing
The dosing of turmeric depends on its formulation. Typicallyreported therapeutic ranges are as follows: 400-600 mg of standardized powder of curcumin given up to three times daily; 1-3 g of dried powdered root is reported to be safety consumed; 30-90 drops of the fluid extract administered daily; and 15-30 drops of the tincture administered 4-times daily. 40 Turmeric is on the list of the United States FDA (Food and Drug Administration) food condiments that are generally considered safe for consumption in foods.
Turmeric and curcumin supplements thus appear to be safe and may provide therapeutic benefits if taken within recommended doses.
However, it should be noted that the effects of these supplements over an extended period of time have not been studied.
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| WHAT IS NE W AND CON CLUS I ON S
Pain is a condition that can significantly impair a person's quality of life. Unfortunately, despite advances in pain research and medications, the adverse effects often associated with short-and long-term use of available agents is still a cause of concern. Therefore, alternatives are desired. A better analgesic is one that provides pain relief and improves a patient's overall quality of life without producing serious adverse effects or the potential for abuse. A number of laboratory studies now suggest that the apparent analgesic properties of curcumin can be attributed to known pain-modulatory mechanisms, and in particular to its ability to reduce inflammation by inhibiting pro-inflammatory mediators: lipoxygenase, cyclooxygenase, leukotrienes, thromboxane, prostaglandins, nitric oxide, collagenase, elastase, hyaluronidase, MCP-1, interferon-inducible protein, tumour necrosis factor and interleukin-12 53 -all of which are known components of pain-transmitting or pain-attenuating pathways. In clinical trials, turmeric has been reported to be effective in alleviating spontaneous pain and sensitization, and to provide these analgesic benefits while maintaining a favourable safety profile. 
